Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2019; 40(S 01): S77-S81
DOI: 10.4103/ijmpo.ijmpo_234_17
Original Article

Profile of Pediatric Chronic Myeloid Leukemia in the Era of Imatinib: A Study from South India

Catherene Bernard
Departments of Pathology, Sri Ramachandra Medical College and Research Institute, Sri Ramachandra University, Chennai, Tamil Nadu, India
,
Febe R Suman
Departments of Pathology, Sri Ramachandra Medical College and Research Institute, Sri Ramachandra University, Chennai, Tamil Nadu, India
,
Rajendran Rashmika
Departments of Pathology, Sri Ramachandra Medical College and Research Institute, Sri Ramachandra University, Chennai, Tamil Nadu, India
,
Magatha Sneha Latha
Departments of Pediatric Hematology Oncology, Sri Ramachandra Medical College and Research Institute, Sri Ramachandra University, Chennai, Tamil Nadu, India
,
Julius Xavier Scott
Departments of Pediatric Hematology Oncology, Sri Ramachandra Medical College and Research Institute, Sri Ramachandra University, Chennai, Tamil Nadu, India
,
V Rajesh
Departments of Pediatric Hematology Oncology, Sri Ramachandra Medical College and Research Institute, Sri Ramachandra University, Chennai, Tamil Nadu, India
› Author Affiliations Financial support and sponsorship This study was financially supported by Summer Research Fellowship, Sri Ramachandra University.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Introduction: Chronic myeloid leukemia (CML), a chronic hematologic malignancy, is rare in pediatric patients. Studies of the tyrosine kinase inhibitor imatinib are required so that uniform guidelines may focus on disease therapy and follow-up for children. We analyzed the clinicohematologic features of the disease, treatment response to imatinib, follow-up measures, and the impact of the disease on the patients and their family. Materials and Methods: All pediatric patients diagnosed with CML and treated and followed-up were studied regarding demographics, clinical features at presentation, and diagnostic profile, including laboratory parameters, peripheral blood smear test, fluorescent in situ hybridization and karyotyping, and reverse-transcriptase polymerase chain reaction for the BCR-ABL fusion gene. Treatment modalities, adverse reactions, remedial measures, assessment at every follow-up visit, patient’s education, parents’ socioeconomic status, and economic and psychological stresses were also evaluated. Results: Six patients were administered upfront therapy with a standard dose of imatinib. Hematological and biochemical parameters were monitored after the drug administration. We assessed the treatment response using molecular detection of the BCR-ABL transcripts. All patients who complied with drug therapy showed a complete molecular response and minimal toxic symptoms. However, parents found it difficult to cope socially and economically. Conclusion: Imatinib mesylate is effective and has a good molecular response, minimal toxicity, and good patient compliance. However, due to its cost, families reacquire financial debt, and the disease creates uncertainty about the child’s future, thereby necessitating psychosocioeconomic support for parents. Changes in the policies of cancer support groups are urgently needed to provide lifelong, lifesaving drugs free of cost.

Keywords

Chronic myeloid leukemia - imatinib - pediatric leukemia - socioeconomic impact


Publication History

Article published online:
24 May 2021

© 2019. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Raut LS. Chronic myeloid leukemia in children: A brief review. Clin Cancer Investing J 2014; 6: 467-71
    Google Scholar
  • 2 Druker BJ, Sawyers CL, Capdeville R, Ford JM, Baccarani M, Goldman JM. et al. Chronic myelogenous leukemia. Hematology Am Soc Hematol Educ Program 2001; 2001: 87-112
    CrossrefPubMedGoogle Scholar
  • 3 Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F. et al. Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European leukemiaNet. Blood 2006; 108: 1809-20
    CrossrefPubMedGoogle Scholar
  • 4 Goldman JM. How I treat chronic myeloid leukemia in the imatinib era. Blood 2007; 110: 2828-37
    CrossrefPubMedGoogle Scholar
  • 5 Kumar N. Kuppuswamy’s socioeconomic status scale-updating for 2007. Indian J Pediatri 2007; 74: 1131-2
    Google Scholar
  • 6 Han HR, Cho EJ, Kim D, Kim J. The report of coping strategies and psychosocial adjustment in Korean mothers of children with cancer. Psychooncology 2009; 18: 956-64
    CrossrefPubMedGoogle Scholar
  • 7 Röllig C, Ehninger G. How I treat hyperleukocytosis in acute myeloid leukemia. Blood 2015; 125: 3246-52
    CrossrefPubMedGoogle Scholar
  • 8 Champagne MA, Capdeville R, Krailo M, Qu W, Peng B, Rosamilia M. et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: Results from a children’s oncology group phase 1 study. Blood 2004; 104: 2655-60
    CrossrefPubMedGoogle Scholar
  • 9 Millot F, Guilhot J, Nelken B, Leblanc T, De Bont ES, Békassy AN. et al. Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation. Leukemia 2006; 20: 187-92
    CrossrefPubMedGoogle Scholar
  • 10 Kolb EA, Pan Q, Ladanyi M, Steinherz PG. Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood. Cancer 2003; 98: 2643-50
    CrossrefPubMedGoogle Scholar
  • 11 Andolina JR, Neudorf SM, Corey SJ. How I treat childhood CML. Blood 2012; 119: 1821-30
    CrossrefPubMedGoogle Scholar
  • 12 Bansal S, Prabhash K, Parikh P. Chronic myeloid leukemia data from India. Indian J Med Paediatr Oncol 2013; 34: 154-8
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Suttorp M. Innovative approaches of targeted therapy for CML of childhood in combination with paediatric haematopoietic SCT. Bone Marrow Transplant 2008; 42 (02) Suppl S40-6
    CrossrefPubMedGoogle Scholar
  • 14 Ray SS, Chakrabarti P, Nath U, Chaudhuri U. A single centre experience of treating CML in a tertiary care centre at Eastern India. 51st National Conference of Indian Society of Hematology and Transfusion Medicine 2010. 18th-21st November. 2010. Kolkata, India: Springer; 2010 129-81
    Google Scholar
  • 15 Burke MJ. Profile of imatinib in pediatric leukemia. Pediatri Health Med Ther 2014; 5: 1-7
    Google Scholar
  • 16 Vardiman JW. Chronic myelogenous leukemia, BCR-ABL1+. Am J Clin Pathol 2009; 132: 250-60
    CrossrefPubMedGoogle Scholar
  • 17 Cwynarski K, Roberts IA, Iacobelli S, van Biezen A, Brand R, Devergie A. et al. Stem cell transplantation for chronic myeloid leukemia in children. Blood 2003; 102: 1224-31
    CrossrefPubMedGoogle Scholar
  • 18 Raut LS. Chronic myeloid leukemia in children. A brief review. Clin Cancer Investig J 2014; 3: 467-71
    CrossrefGoogle Scholar
  • 19 Muramatsu H, Kojima S, Yoshimi A, Atsuta Y, Kato K, Nagatoshi Y. et al. Outcome of 125 children with chronic myelogenous leukemia who received transplants from unrelated donors: The Japan Marrow Donor Program. Biol Blood Marrow Transplant 2010; 16: 231-8
    CrossrefPubMedGoogle Scholar
  • 20 Millot F, Baruchel A, Guilhot J, Petit A, Leblanc T, Bertrand Y. et al. Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: Results of the French national phase IV trial. J Clin Oncol 2011; 29: 2827-32
    CrossrefPubMedGoogle Scholar
  • 21 Raut L, Bohara VV, Ray SS, Chakrabarti P, Chaudhuri U. Chronic myeloid leukemia in children and adolescents: A single center experience from Eastern India. South Asian J Cancer 2013; 2: 260-4
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Linga VG, Ganta RR, Kalpathi KI, Gundeti S, Rajappa SJ, Digumarti R. et al. Response to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase. South Asian J Cancer 2014; 3: 203-5
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Ghadyalpatil N, Banawali S, Kurkure P, Arora B, Bansal S, Amare P. Efficacy and tolerability of imatinib mesylate in pediatric chronic myeloid leukemia in a large cohort: Results from a tertiary care referral centre in India. J Clin Oncol 2009; 27: 15s
    CrossrefPubMedGoogle Scholar
  • 24 Shima H, Tokuyama M, Tanizawa A, Tono C, Hamamoto K, Muramatsu H. et al. Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia. J Pediatr 2011; 159: 676-81
    CrossrefPubMedGoogle Scholar
  • 25 Ganesan P, Rajendranath R, Kandakumar V, Sagar TG. Treatment of chronic phase chronic myeloid leukemia with imatinib. Indian J Pediatr 2015; 82: 235-9
    CrossrefPubMedGoogle Scholar
  • 26 Rao GP, Malhotra S, Marwaha RK. Psychosocial study of leukemic children and their parents. Indian Pediatr 1992; 29: 985-90
    PubMedGoogle Scholar
  • 27 Bayat M, Erdem E, Gül Kuzucu E. Depression, anxiety, hopelessness, and social support levels of the parents of children with cancer. J Pediatr Oncol Nurs 2008; 25: 247-53
    CrossrefPubMedGoogle Scholar
  • 28 Kohlsdorf M, Junior ALC. Psychosocial impact of pediatric cancer on parents: A literature review. Paideia 2012; 22: 119-29
    CrossrefGoogle Scholar
  • 29 Klassen AF, Klaassen R, Dix D, Pritchard S, Yanofsky R, O’Donnell M. et al. Impact of caring for a child with cancer on parents’ health-related quality of life. J Clin Oncol 2008; 26: 5884-9
    CrossrefPubMedGoogle Scholar